AMENDMENT NO. 6 TO DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • April 7th, 2011 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 6 (“Amendment No. 6”) to the Development, License and Commercialization Agreement is made and effective as of the 6th day of April, 2011 (“Amendment Effective Date”) between Idenix Pharmaceuticals, Inc., with offices at 60 Hampshire Street, Cambridge Massachusetts 02139, USA (“Idenix US”), Idenix (Cayman) Limited with offices c/o Walkers SPV Limited, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands (“Idenix Cayman” and together with Idenix US, “Idenix”) and Novartis Pharma AG with offices at Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novartis”).
AMENDMENT NO. 1 TO STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • April 7th, 2011 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 (“Amendment No. 1”) to the Stockholders’ Agreement is made and effective as of the 6th day of April, 2011 (“Amendment Effective Date”) among Idenix Pharmaceuticals, Inc., with offices at 60 Hampshire Street, Cambridge Massachusetts 02139, USA (“Idenix US”), Novartis Pharma AG with offices at Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novartis”) and those other parties set forth on Exhibit A to the Stockholders’ Agreement.
